NVCR NovoCure Limited Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

NVCR [NASD]

NovoCure Limited

Healthcare | Medical Instruments & Supplies | USA

statements

Index	-	P/E	43980.00	EPS (ttm)	0.00	Insider Own	1.60%	Shs Outstand	100.72M	Perf Week	-2.24%
Market Cap	13.04B	Forward P/E	429.77	EPS next Y	0.31	Insider Trans	-25.50%	Shs Float	84.43M	Perf Month	25.53%
Income	0.50M	PEG	-	EPS next Q	0.04	Inst Own	69.40%	Short Float	6.32%	Perf Quarter	97.40%
Sales	409.00M	P/S	31.87	EPS this Y	89.30%	Inst Trans	0.17%	Short Ratio	5.38	Perf Half Y	82.44%
Book/sh	2.66	P/B	49.60	EPS next Y	107.43%	ROA	2.40%	Target Price	112.00	Perf Year	75.36%
Cash/sh	3.51	P/C	37.60	EPS next 5Y	-	ROE	5.10%	52W Range	53.40 - 140.89	Perf YTD	56.57%
Dividend	-	P/FCF	609.14	EPS past 5Y	40.20%	ROI	0.20%	52W High	-6.35%	Beta	1.43
Dividend %	-	Quick Ratio	5.40	Sales past 5Y	86.70%	Gross Margin	76.10%	52W Low	147.08%	ATR	5.71
Employees	782	Current Ratio	5.70	Sales Q/Q	33.70%	Oper. Margin	1.80%	RSI (14)	68.57	Volatility	3.61% 4.24%
Optionable	Yes	Debt/Eq	0.56	EPS Q/Q	216.60%	Profit Margin	2.90%	Rel Volume	0.64	Prev Close	132.34
Shortable	Yes	LT Debt/Eq	0.56	Earnings	Oct 29 BMO	Payout	0.00%	Avg Volume	991.52K	Price	131.94
Recom	2.80	SMA20	9.21%	SMA50	32.45%	SMA200	68.33%	Volume	630,236	Change	-0.30%

Sep-23-20

Initiated

Northland Capital

Outperform

$200

Sep-18-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$116

Sep-17-20

Downgrade

Truist

Buy → Hold

$108

Jun-01-20

Resumed

Oppenheimer

Perform

May-01-20

Downgrade

Oppenheimer

Outperform → Perform

Apr-09-20

Downgrade

Evercore ISI

In-line → Underperform

$58

Mar-05-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$85 → $90

Jan-02-20

Downgrade

Evercore ISI

Outperform → In-line

$84 → $90

Jul-29-19

Upgrade

SunTrust

Hold → Buy

Jul-26-19

Downgrade

Wedbush

Outperform → Neutral

$57 → $80

Jul-26-19

Downgrade

JP Morgan

Overweight → Neutral

$61 → $79

Mar-20-19

Initiated

SunTrust

Hold

Nov-02-18

Downgrade

Wells Fargo

Outperform → Market Perform

Jul-16-18

Initiated

Evercore ISI

Outperform

$46

Apr-18-18

Reiterated

Mizuho

Buy

$28 → $32

Feb-23-18

Reiterated

Mizuho

Buy

$25 → $28

May-24-17

Upgrade

Wells Fargo

Market Perform → Outperform

Jul-29-16

Reiterated

Wedbush

Outperform

$30 → $20

Jan-19-16

Initiated

Barclays

Underweight

$16

Dec-02-15

Initiated

Deutsche Bank

Hold

$28

Oct-09-20 08:23AM	3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic Zacks +7.30%
Oct-07-20 12:11PM	Jabil, Harley-Davidson, TMO, LHCG and NovoCure as Zacks Bull and Bear of the Day Zacks +6.43%
Oct-05-20 03:27PM	NovoCure Surges to New Highs: Here's the Technical Road Ahead TheStreet.com
Oct-02-20 11:30AM	Is NovoCure (NVCR) Outperforming Other Medical Stocks This Year? Zacks
08:56AM	Novocure to Report Third Quarter 2020 Financial Results Business Wire
Sep-29-20 07:30AM	Novocure to Host Virtual Research & Development Day Business Wire
Sep-28-20 08:43PM	Hedge Funds Are Done Buying NovoCure Limited (NVCR) Insider Monkey
Sep-25-20 04:00PM	Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community Business Wire
Sep-24-20 12:41PM	Novocure Steady After Breakout Investor's Business Daily Video
Sep-23-20 11:25AM	Here's What We Think About NovoCure's (NASDAQ:NVCR) CEO Pay Simply Wall St.
Sep-09-20 03:12PM	Dow Jones Retraces A Third Of Its 1,735-Point Loss; Will These Growth Stocks Recover? Investor's Business Daily
Sep-04-20 07:30AM	Novocure to Participate in the 2020 Wells Fargo Virtual Healthcare Conference Business Wire
Aug-29-20 08:00AM	Intuitive Surgical, Edwards Lifesciences Lead Five Top Stocks To Watch As Coronavirus Cases Fall, Elective Procedures Rise Investor's Business Daily
Aug-24-20 03:29PM	NovoCure (NASDAQ:NVCR) Shareholders Have Enjoyed An Impressive 290% Share Price Gain Simply Wall St.
Aug-13-20 11:37AM	Understanding NovoCure's Unusual Options Activity Benzinga
08:30AM	Novocure Announces Expansion of Its Executive Leadership Team Business Wire
Jul-30-20 09:01PM	NovoCure (NVCR) Q2 2020 Earnings Call Transcript Motley Fool +12.01%
06:00AM	Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update Business Wire
Jul-28-20 07:30AM	Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program Business Wire
Jul-24-20 09:37PM	3 Great Healthcare Stocks to Watch Motley Fool
Jul-23-20 12:33PM	NovoCure (NVCR) Q2 Earnings Preview: What's in the Cards? Zacks
12:00PM	What Type Of Shareholders Make Up NovoCure Limited's (NASDAQ:NVCR) Share Registry? Simply Wall St.
Jul-22-20 07:30AM	First Patient Enrolled in Novocures EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays Business Wire +5.33%
Jul-15-20 04:38PM	Dow Jones Giant Merck Inks A New Deal In Lung Cancer And Shares Pop Investor's Business Daily +9.46%
09:10AM	Merck, Novocure Team Up On Lung Cancer Treatment; Trial Set For 2H20 SmarterAnalyst
07:30AM	Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer Business Wire
Jul-12-20 08:54PM	Did Hedge Funds Make The Right Call On NovoCure Limited (NVCR) ? Insider Monkey
Jul-08-20 07:30AM	Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua Business Wire
06:00AM	The 2 Little-Known Growth Stocks I Bought Last Week Motley Fool
Jul-07-20 07:30AM	Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer Business Wire -5.22%
Jul-01-20 07:30AM	Novocure to Report Second Quarter 2020 Financial Results Business Wire
Jun-18-20 12:02PM	Has NovoCure Limited (NASDAQ:NVCR) Stock's Recent Performance Got Anything to Do With Its Financial Health? Simply Wall St.
Jun-08-20 01:07AM	Hedge Funds Have Never Been This Bullish On NovoCure Limited (NVCR) Insider Monkey
Jun-02-20 07:30AM	Novocure Announces Launch of MyLink to Enable Patient-Guided, Remote Download of Optune® Usage Data Business Wire
May-13-20 10:10AM	China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Business Wire
May-05-20 11:30PM	Edited Transcript of NVCR earnings conference call or presentation 30-Apr-20 12:00pm GMT Thomson Reuters StreetEvents
May-04-20 10:21AM	Is NovoCure Limited (NASDAQ:NVCR) Potentially Undervalued? Simply Wall St.
May-02-20 11:30AM	NovoCure Limited (NVCR) Q1 2020 Earnings Call Transcript Motley Fool
Apr-30-20 04:05PM	Highly Rated Cancer Play Tumbles As Key Studies Delayed Amid Outbreak Investor's Business Daily -10.52%
07:30AM	NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates Zacks
06:00AM	Novocure Reports First Quarter 2020 Financial Results and Provides Company Update Business Wire
Apr-27-20 07:30AM	Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I Business Wire
Apr-23-20 12:32PM	NovoCure (NVCR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Apr-07-20 03:07PM	Is NovoCure (NASDAQ:NVCR) A Risky Investment? Simply Wall St. -6.60%
09:00AM	Medical Services Outlook Bright Amid Coronavirus Crisis Zacks
Apr-03-20 07:30AM	Novocure Provides Business Update Related to COVID-19 Business Wire
Mar-23-20 12:24AM	Hedge Funds Started Selling NovoCure Limited (NVCR) Before The Coronavirus Insider Monkey
Mar-20-20 09:16AM	German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany Business Wire -6.68%
Mar-19-20 07:30AM	Novocure Announces Optune Lua as the Brand Name for the NovoTTF-100L System Business Wire +9.50%
Mar-12-20 07:30AM	Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy Business Wire
Mar-10-20 03:18AM	Edited Transcript of NVCR earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-27-20 07:30AM	NovoCure (NVCR) Q4 Earnings and Revenues Beat Estimates Zacks
06:00AM	Novocure Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Company Update Business Wire
Feb-20-20 12:31PM	NovoCure (NVCR) Earnings Expected to Grow: Should You Buy? Zacks
Feb-11-20 08:54AM	Is NovoCure Limited's (NASDAQ:NVCR) CEO Paid Enough Relative To Peers? Simply Wall St.
Feb-05-20 09:15AM	NASDAQ Reaches New Closing High as Rebound Continues Zacks
Feb-04-20 02:56PM	Expand Your Portfolio with this First Profit Stock Screener Zacks
Jan-29-20 09:15AM	Relief Rally Snaps the Dow's 5-Day Losing Skid Zacks
Jan-23-20 07:24AM	The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment Benzinga
Jan-21-20 04:35PM	Why This Leading Medtech Stock Nabbed A Second Breakout In A Week Investor's Business Daily
07:40AM	Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Business Wire
Jan-17-20 10:17AM	Stock Market Sets More Record Highs; Home Depot, Pinterest, Tesla, Twitter Key Movers Investor's Business Daily
Jan-16-20 04:45PM	IBD Stock Of The Day Breaks Out On Bullish Preliminary Sales Report Investor's Business Daily +11.84%
Jan-13-20 06:00AM	Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update Business Wire
Jan-09-20 07:30AM	Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer GlobeNewswire
Jan-03-20 08:40AM	Small-cap woes highlight stock markets dependency on mega-cap names MarketWatch
Dec-26-19 07:30AM	Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-08-19 07:11PM	Heres What Hedge Funds Think About NovoCure Limited (NVCR) Insider Monkey
Dec-04-19 04:05PM	SI-BONE Names Jeryl (Jeri) Hilleman to Board of Directors GlobeNewswire
09:55AM	Raise Stops on NovoCure TheStreet.com
Dec-02-19 07:30AM	Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program Business Wire
05:00AM	Novocure- A New Way to Target Tumors MoneyShow
Nov-26-19 07:30AM	Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference TEST Business Wire Releases
07:30AM	Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference Business Wire
Nov-20-19 07:30AM	Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-04-19 09:35AM	Edited Transcript of NVCR earnings conference call or presentation 31-Oct-19 12:00pm GMT Thomson Reuters StreetEvents
Nov-01-19 11:10AM	NovoCure Looks Ready to Resume Its Strong Uptrend After a Correction TheStreet.com +5.19%
Oct-31-19 07:35AM	NovoCure (NVCR) Q3 Earnings and Revenues Beat Estimates Zacks
06:00AM	Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update Business Wire
06:00AM	Novocure Ltd. to Host Earnings Call ACCESSWIRE
Oct-27-19 10:08AM	3 Monster Growth Stocks to Hold Through 2020 TipRanks
Oct-24-19 10:32AM	Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-18-19 07:35AM	Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Oct-16-19 10:31AM	Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology Business Wire
Oct-14-19 06:13PM	Did Hedge Funds Drop The Ball On NovoCure Limited (NVCR) ? Insider Monkey
01:31PM	How Many NovoCure Limited (NASDAQ:NVCR) Shares Have Insiders Sold, In The Last Year? Simply Wall St.
Oct-01-19 07:30AM	Novocure to Report Third Quarter 2019 Financial Results Business Wire
Sep-13-19 06:59PM	Novocure (NVCR) CFO Wilhelmus Cm Groenhuysen Sold $3.9 million of Shares GuruFocus.com
Sep-11-19 07:15PM	Novocure (NVCR) CFO Wilhelmus Cm Groenhuysen Sold $3.9 million of Shares GuruFocus.com
Sep-09-19 11:34AM	10 Stocks to Sell in Market-Cursed September InvestorPlace -8.23%
09:25AM	Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting Business Wire
Sep-04-19 09:44AM	Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Aug-30-19 06:54PM	Small-Cap Stocks Show Stealth Buying Pattern Investopedia
Aug-29-19 08:50AM	Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load? Simply Wall St.
Aug-27-19 11:37AM	Jim Cramer Gives His Opinion On Novocure, Morgan Stanley And More Benzinga
Aug-14-19 05:38AM	Novocure's Charts Are as Bullish As They Get, So Here's My Strategy TheStreet.com
Aug-13-19 07:01AM	Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Aug-12-19 07:30AM	China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China GlobeNewswire
07:30AM	China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China Business Wire
Aug-07-19 11:17AM	Jim Cramer Weighs In On Funko, Citigroup And More Benzinga

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weinberg Uri	Chief Science Officer	Sep 25	Option Exercise	9.62	15,250	146,750	36,347	Sep 28 06:13 PM
Weinberg Uri	Chief Science Officer	Sep 25	Sale	103.35	15,250	1,576,088	27,597	Sep 28 06:13 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 18	Option Exercise	7.48	8,262	61,800	150,869	Sep 21 04:16 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 18	Sale	109.21	8,262	902,294	142,607	Sep 21 04:16 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 17	Option Exercise	7.48	12,500	93,500	155,107	Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 17	Sale	108.60	12,500	1,357,556	142,607	Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 16	Option Exercise	7.29	22,012	160,369	155,107	Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 16	Sale	107.35	22,012	2,363,014	142,607	Sep 18 04:37 PM
LEUNG GABRIEL	Director	Sep 15	Option Exercise	7.48	9,565	71,546	79,437	Sep 16 05:27 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 15	Option Exercise	7.37	50,868	374,868	155,975	Sep 16 05:24 PM
Danziger Asaf	Chief Executive Officer	Sep 15	Option Exercise	22.00	103,000	2,266,000	300,632	Sep 17 04:32 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 15	Sale	103.27	50,868	5,253,018	142,607	Sep 16 05:24 PM
LEUNG GABRIEL	Director	Sep 15	Sale	100.00	9,565	956,500	72,045	Sep 16 05:27 PM
Danziger Asaf	Chief Executive Officer	Sep 15	Sale	99.00	103,000	10,197,000	197,632	Sep 17 04:32 PM
LEUNG GABRIEL	Director	Sep 14	Option Exercise	7.48	10,000	74,800	82,045	Sep 16 05:27 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 14	Option Exercise	7.03	25,000	175,750	155,107	Sep 16 05:24 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 14	Sale	98.01	25,000	2,450,213	142,607	Sep 16 05:24 PM
LEUNG GABRIEL	Director	Sep 14	Sale	95.00	10,000	950,000	72,045	Sep 16 05:27 PM
LEUNG GABRIEL	Director	Sep 10	Option Exercise	7.48	10,000	74,800	82,045	Sep 11 04:15 PM
LEUNG GABRIEL	Director	Sep 10	Sale	90.00	10,000	900,000	72,045	Sep 11 04:15 PM
LEUNG GABRIEL	Director	Sep 09	Option Exercise	7.03	9,114	64,071	81,159	Sep 11 04:15 PM
LEUNG GABRIEL	Director	Sep 09	Sale	85.40	9,114	778,293	72,045	Sep 11 04:15 PM
Shah Pritesh	Chief Commercial Officer	Sep 09	Sale	85.41	28,321	2,418,881	70,465	Sep 11 04:19 PM
LEUNG GABRIEL	Director	Sep 02	Option Exercise	7.03	100	703	72,145	Sep 04 04:17 PM
LEUNG GABRIEL	Director	Sep 02	Sale	85.00	100	8,500	72,045	Sep 04 04:17 PM
LEUNG GABRIEL	Director	Aug 25	Option Exercise	7.03	7,112	49,997	79,157	Aug 27 04:13 PM
LEUNG GABRIEL	Director	Aug 25	Sale	80.13	7,112	569,892	72,045	Aug 27 04:13 PM
Shah Pritesh	Chief Commercial Officer	Aug 04	Sale	76.81	2,048	157,307	101,018	Aug 05 04:13 PM
Shah Pritesh	Chief Commercial Officer	Aug 03	Sale	76.41	1,669	127,522	103,066	Aug 05 04:13 PM
Benaim Ely	Chief Medical Officer	Aug 03	Sale	76.06	660	50,200	29,356	Aug 05 04:11 PM
Shah Pritesh	Chief Commercial Officer	Jul 31	Option Exercise	76.17	3,717	283,124	104,735	Aug 03 05:39 PM
Benaim Ely	Chief Medical Officer	Jul 31	Sale	76.39	341	26,048	30,016	Aug 03 05:53 PM
DOYLE WILLIAM F	Executive Chairman	Jul 31	Sale	76.39	896	68,444	649,062	Aug 03 05:51 PM
LEUNG GABRIEL	Director	Jul 30	Option Exercise	7.03	7,112	49,997	79,157	Aug 03 05:45 PM
LEUNG GABRIEL	Director	Jul 30	Sale	75.00	7,112	533,400	72,045	Aug 03 05:45 PM
Ambrogi Michael J.	Chief Operating Officer	Jul 22	Option Exercise	18.40	42,972	790,640	251,639	Jul 23 07:43 PM
LEUNG GABRIEL	Director	Jul 22	Option Exercise	7.03	9,500	66,785	81,545	Jul 23 07:32 PM
Ambrogi Michael J.	Chief Operating Officer	Jul 22	Sale	67.02	42,972	2,879,966	220,867	Jul 23 07:43 PM
LEUNG GABRIEL	Director	Jul 22	Sale	67.03	9,500	636,797	72,045	Jul 23 07:32 PM
Ambrogi Michael J.	Chief Operating Officer	Jul 21	Option Exercise	20.27	3,321	67,332	223,888	Jul 23 07:43 PM
LEUNG GABRIEL	Director	Jul 21	Option Exercise	7.03	500	3,515	72,545	Jul 23 07:32 PM
Ambrogi Michael J.	Chief Operating Officer	Jul 21	Sale	65.06	3,321	216,072	220,867	Jul 23 07:43 PM
LEUNG GABRIEL	Director	Jul 21	Sale	65.07	500	32,537	72,045	Jul 23 07:32 PM
Benaim Ely	Chief Medical Officer	May 12	Sale	64.78	2,595	168,104	12,616	May 14 04:14 PM
DOYLE WILLIAM F	Executive Chairman	May 11	Sale	63.73	31,332	1,996,726	649,958	May 12 04:13 PM
Benaim Ely	Chief Medical Officer	May 11	Sale	63.73	1,611	102,666	15,211	May 12 04:22 PM
DOYLE WILLIAM F	Executive Chairman	May 08	Option Exercise	63.84	58,767	3,751,685	713,193	May 11 04:17 PM
Benaim Ely	Chief Medical Officer	May 08	Option Exercise	63.84	4,206	268,511	16,822	May 12 04:22 PM
Weinberg Uri	Chief Science Officer	May 08	Option Exercise	63.84	1,402	89,504	25,629	May 11 04:22 PM
DOYLE WILLIAM F	Executive Chairman	May 08	Sale	63.50	31,903	2,025,872	681,290	May 11 04:17 PM
DOYLE WILLIAM F	Executive Chairman	May 07	Option Exercise	64.77	58,768	3,806,403	685,419	May 11 04:17 PM
DOYLE WILLIAM F	Executive Chairman	May 07	Sale	64.74	30,993	2,006,518	654,426	May 11 04:17 PM
DOYLE WILLIAM F	Executive Chairman	May 06	Option Exercise	64.15	58,768	3,769,967	626,651	May 07 04:41 PM
DOYLE WILLIAM F	Executive Chairman	May 06	Sale	64.27	29,881	1,920,452	567,883	May 07 04:41 PM
DOYLE WILLIAM F	Executive Chairman	May 05	Option Exercise	61.40	58,768	3,608,355	628,047	May 07 04:41 PM
Shah Pritesh	Chief Commercial Officer	May 05	Sale	62.20	1,149	71,468	100,693	May 07 04:48 PM
DOYLE WILLIAM F	Executive Chairman	May 05	Sale	62.47	30,283	1,891,718	597,764	May 07 04:41 PM
DOYLE WILLIAM F	Executive Chairman	May 04	Option Exercise	60.48	58,768	3,554,289	569,279	May 06 05:52 PM
Shah Pritesh	Chief Commercial Officer	May 04	Sale	60.08	1,184	71,134	101,842	May 05 04:32 PM
Shah Pritesh	Chief Commercial Officer	May 01	Option Exercise	65.80	2,333	153,511	103,026	May 05 04:32 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 14	Option Exercise	7.15	35,745	255,577	256,612	Apr 15 05:03 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 14	Sale	71.00	27,519	1,953,970	220,867	Apr 15 05:03 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 13	Option Exercise	7.15	22,755	162,698	243,622	Apr 15 05:03 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 13	Sale	69.32	30,981	2,147,594	220,867	Apr 15 05:03 PM
Shah Pritesh	Chief Commercial Officer	Mar 06	Option Exercise	7.48	17,500	130,900	103,938	Mar 10 04:20 PM
DOYLE WILLIAM F	Executive Chairman	Mar 06	Sale	69.53	4,320	300,387	510,511	Mar 10 04:18 PM
Longsworth Todd Christopher	General Counsel	Mar 06	Sale	69.53	2,499	173,765	86,753	Mar 10 04:15 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Mar 06	Sale	69.53	3,123	217,155	140,386	Mar 10 04:13 PM
Shah Pritesh	Chief Commercial Officer	Mar 06	Sale	66.76	6,151	410,622	86,438	Mar 10 04:20 PM
Ambrogi Michael J.	Chief Operating Officer	Mar 06	Sale	69.53	2,274	158,120	220,867	Mar 10 04:22 PM
Shah Pritesh	Chief Commercial Officer	Mar 02	Sale	72.97	1,485	108,360	67,721	Mar 05 04:47 PM
Longsworth Todd Christopher	General Counsel	Feb 28	Sale	72.22	2,643	190,864	70,032	Mar 02 05:11 PM
DOYLE WILLIAM F	Executive Chairman	Feb 28	Sale	72.22	3,893	281,133	514,831	Mar 02 05:13 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 28	Sale	72.22	2,673	193,031	208,726	Mar 02 05:17 PM
Shah Pritesh	Chief Commercial Officer	Feb 28	Sale	72.22	1,601	115,616	69,206	Mar 02 05:22 PM
Shah Pritesh	Chief Commercial Officer	Feb 27	Option Exercise	79.45	3,086	245,183	70,807	Mar 02 05:22 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 27	Option Exercise	0.00	7,716	0	119,484	Mar 02 05:18 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 27	Option Exercise	79.45	6,173	490,445	211,399	Mar 02 05:17 PM
Danziger Asaf	Chief Executive Officer	Feb 27	Option Exercise	79.45	9,259	735,628	197,348	Mar 02 05:15 PM
DOYLE WILLIAM F	Executive Chairman	Feb 27	Option Exercise	79.45	9,259	735,628	518,724	Mar 02 05:13 PM
Longsworth Todd Christopher	General Counsel	Feb 27	Option Exercise	79.45	5,556	441,424	72,675	Mar 02 05:11 PM
Shah Pritesh	Chief Commercial Officer	Feb 26	Sale	79.39	7,932	629,725	67,721	Feb 28 04:41 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 25	Sale	81.16	11,647	945,224	205,226	Feb 26 05:10 PM
Longsworth Todd Christopher	General Counsel	Feb 25	Sale	81.16	8,482	688,365	67,119	Feb 26 05:14 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 25	Sale	81.16	18,908	1,534,498	111,768	Feb 26 05:17 PM
Shah Pritesh	Chief Commercial Officer	Feb 25	Sale	81.16	5,067	411,217	75,653	Feb 28 04:41 PM
Danziger Asaf	Chief Executive Officer	Feb 24	Option Exercise	88.26	53,333	4,707,171	188,089	Feb 26 05:19 PM
Shah Pritesh	Chief Commercial Officer	Feb 24	Option Exercise	88.26	12,999	1,147,292	80,720	Feb 26 05:18 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 24	Option Exercise	88.26	43,333	3,824,571	130,676	Feb 26 05:17 PM
Longsworth Todd Christopher	General Counsel	Feb 24	Option Exercise	88.26	21,666	1,912,241	75,601	Feb 26 05:14 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 24	Option Exercise	88.26	31,199	2,753,624	216,873	Feb 26 05:10 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 22	Option Exercise	7.03	2,915	20,492	88,858	Jan 24 07:11 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 22	Sale	98.14	2,915	286,084	87,343	Jan 24 07:11 PM
DOYLE WILLIAM F	Executive Chairman	Jan 17	Sale	95.00	133,777	12,708,815	509,465	Jan 22 04:19 PM
PHILLIPS CHARLES G III	Director	Dec 02	Sale	88.11	6,145	541,448	3,359	Dec 04 04:23 PM
LEUNG GABRIEL	Director	Nov 25	Option Exercise	7.03	20,000	140,600	89,504	Nov 26 04:23 PM
Danziger Asaf	Chief Executive Officer	Nov 25	Option Exercise	22.00	103,000	2,266,000	237,601	Nov 26 04:28 PM
LEUNG GABRIEL	Director	Nov 25	Sale	95.00	20,000	1,900,000	69,504	Nov 26 04:23 PM
Danziger Asaf	Chief Executive Officer	Nov 25	Sale	95.00	103,000	9,785,000	134,601	Nov 26 04:28 PM
DOYLE WILLIAM F	Executive Chairman	Nov 25	Sale	96.04	16,223	1,558,057	643,242	Nov 26 04:29 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience